Bioxytran, Inc. (BIXT)
USD 0.13
(-15.4%)
USD 0.13
(-15.4%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -3.82 Million USD | -79.0% |
| 2022 | -2.13 Million USD | 49.36% |
| 2021 | -4.21 Million USD | -232.18% |
| 2020 | -1.26 Million USD | 22.24% |
| 2019 | -1.63 Million USD | -659.85% |
| 2018 | -214.71 Thousand USD | 30.87% |
| 2017 | -310.58 Thousand USD | 53.73% |
| 2016 | -671.27 Thousand USD | 67.92% |
| 2015 | -2.09 Million USD | -63.37% |
| 2014 | -1.28 Million USD | 35.07% |
| 2013 | -1.97 Million USD | 13.85% |
| 2012 | -2.28 Million USD | 2.73% |
| 2011 | -2.35 Million USD | -615.44% |
| 2010 | -329.03 Thousand USD | -20.9% |
| 2009 | -272.14 Thousand USD | -1023.89% |
| 2008 | -24.21 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -785.82 Thousand USD | 23.75% |
| 2024 Q3 | -346.2 Thousand USD | 43.33% |
| 2024 Q2 | -610.92 Thousand USD | 22.26% |
| 2023 Q2 | -1.02 Million USD | -36.09% |
| 2023 Q3 | 50.5 Thousand USD | 104.94% |
| 2023 Q4 | -1.03 Million USD | -2140.51% |
| 2023 FY | -3.82 Million USD | -79.39% |
| 2023 Q1 | -750.75 Thousand USD | 5.21% |
| 2022 Q2 | -537.22 Thousand USD | 41.05% |
| 2022 Q1 | -911.35 Thousand USD | 2.63% |
| 2022 FY | -2.13 Million USD | 49.36% |
| 2022 Q4 | -792 Thousand USD | -5667.72% |
| 2022 Q3 | 14.22 Thousand USD | 102.65% |
| 2021 Q1 | -1.68 Million USD | -117.56% |
| 2021 Q3 | -547.24 Thousand USD | 47.5% |
| 2021 FY | -4.21 Million USD | -232.18% |
| 2021 Q4 | -935.96 Thousand USD | -71.03% |
| 2021 Q2 | -1.04 Million USD | 38.28% |
| 2020 Q3 | -114.44 Thousand USD | -2.27% |
| 2020 FY | -1.26 Million USD | 22.24% |
| 2020 Q2 | -111.9 Thousand USD | 57.94% |
| 2020 Q1 | -266.04 Thousand USD | 46.76% |
| 2020 Q4 | -776.3 Thousand USD | -578.3% |
| 2019 FY | -1.63 Million USD | -659.85% |
| 2019 Q4 | -499.66 Thousand USD | 41.24% |
| 2019 Q2 | -106.49 Thousand USD | 17.84% |
| 2019 Q1 | -129.62 Thousand USD | 22.03% |
| 2019 Q3 | -850.31 Thousand USD | -698.44% |
| 2018 Q2 | -112.67 Thousand USD | -307.29% |
| 2018 Q4 | -166.24 Thousand USD | -249.8% |
| 2018 FY | -214.71 Thousand USD | 30.87% |
| 2018 Q1 | -27.66 Thousand USD | 67.99% |
| 2018 Q3 | -47.52 Thousand USD | 57.82% |
| 2017 Q3 | 50.83 Thousand USD | 119.67% |
| 2017 FY | -310.58 Thousand USD | 53.73% |
| 2017 Q1 | -62.63 Thousand USD | -145.64% |
| 2017 Q4 | -86.41 Thousand USD | -269.99% |
| 2017 Q2 | -258.46 Thousand USD | -312.65% |
| 2016 FY | -671.27 Thousand USD | 67.92% |
| 2016 Q4 | 137.22 Thousand USD | 164.72% |
| 2016 Q1 | -453.09 Thousand USD | -29.73% |
| 2016 Q3 | -212.04 Thousand USD | -47.89% |
| 2016 Q2 | -143.37 Thousand USD | 68.36% |
| 2015 FY | -2.09 Million USD | -63.37% |
| 2015 Q1 | -37.2 Thousand USD | 78.86% |
| 2015 Q2 | -1.91 Million USD | -5044.08% |
| 2015 Q3 | 208.2 Thousand USD | 110.88% |
| 2015 Q4 | -349.26 Thousand USD | -267.75% |
| 2014 Q2 | -56.15 Thousand USD | -185.4% |
| 2014 Q3 | -1.11 Million USD | -1884.21% |
| 2014 FY | -1.28 Million USD | 35.07% |
| 2014 Q4 | -175.98 Thousand USD | 84.21% |
| 2014 Q1 | 65.75 Thousand USD | 170.8% |
| 2013 Q4 | -92.87 Thousand USD | 66.23% |
| 2013 FY | -1.97 Million USD | 13.85% |
| 2013 Q1 | -962.77 Thousand USD | -44.74% |
| 2013 Q2 | -631.6 Thousand USD | 34.4% |
| 2013 Q3 | -275.03 Thousand USD | 56.45% |
| 2012 Q1 | -32.41 Thousand USD | 97.44% |
| 2012 Q2 | -191.59 Thousand USD | -491.0% |
| 2012 Q4 | -665.19 Thousand USD | -36.79% |
| 2012 Q3 | -486.28 Thousand USD | -153.82% |
| 2012 FY | -2.28 Million USD | 2.73% |
| 2011 Q4 | -1.26 Million USD | -459.48% |
| 2011 FY | -2.35 Million USD | -615.44% |
| 2011 Q2 | -138.76 Thousand USD | 80.8% |
| 2011 Q1 | -722.78 Thousand USD | -1026.59% |
| 2011 Q3 | -226.3 Thousand USD | -63.08% |
| 2010 Q4 | -64.15 Thousand USD | 8.05% |
| 2010 FY | -329.03 Thousand USD | -20.9% |
| 2010 Q2 | -120.51 Thousand USD | -62.34% |
| 2010 Q1 | -74.23 Thousand USD | 46.31% |
| 2010 Q3 | -69.77 Thousand USD | 42.1% |
| 2009 Q4 | -138.27 Thousand USD | -62.41% |
| 2009 Q3 | -85.14 Thousand USD | -134.04% |
| 2009 Q1 | -12.87 Thousand USD | 0.0% |
| 2009 Q2 | -36.37 Thousand USD | -182.6% |
| 2009 FY | -272.14 Thousand USD | -1023.89% |
| 2008 FY | -24.21 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -186.061% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 24.271% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 78.595% |
| Nascent Biotech, Inc. | -2.22 Million USD | -71.316% |
| Rebus Holdings, Inc. | -664 Thousand USD | -475.323% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 104.667% |
| Qrons Inc. | -643.67 Thousand USD | -493.488% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -880.606% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 93.118% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -819.456% |
| Skye Bioscience, Inc. | -13.67 Million USD | 72.058% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 94.678% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 177.727% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -1359.598% |
| SQZ Biotechnologies Company | -75.82 Million USD | 94.962% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -34.016% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -148.7% |
| Mesoblast Limited | -84.14 Million USD | 95.46% |
| Marizyme, Inc. | -34.08 Million USD | 88.793% |
| Genus plc | 6.4 Million USD | 159.69% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 139.211% |
| Pharming Group N.V. | -4.87 Million USD | 21.711% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -92.307% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -310.16% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 54.25% |
| ContraFect Corporation | -56.88 Million USD | 93.285% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 16.128% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -172.48% |
| IMV Inc. | -38.67 Million USD | 90.122% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -38.872% |
| MultiCell Technologies, Inc. | -722.81 USD | -528413.302% |
| ONE Bio Corp. | 13.68 Million USD | 127.922% |
| Accustem Sciences Inc. | -3.74 Million USD | -1.968% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 93.524% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -690.819% |
| Q BioMed Inc. | -3.44 Million USD | -10.87% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 207.914% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -45.39% |
| Biomind Labs Inc. | -1 Million USD | -278.381% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 93.051% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -31.672% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 42.537% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -104.903% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -12654.23% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 75.928% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -97.668% |
| GB Sciences, Inc. | -1.42 Million USD | -168.928% |
| Alpha Cognition Inc. | -9.7 Million USD | 60.64% |
| HST Global, Inc. | -140.9 Thousand USD | -2611.112% |
| CSL Limited | 3.7 Billion USD | 100.103% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -239.597% |
| Halberd Corporation | -75.05 Thousand USD | -4990.136% |
| Enzolytics Inc. | -2.14 Million USD | -77.78% |
| Agentix Corp. | -1.37 Million USD | -178.486% |
| Resverlogix Corp. | -12.74 Million USD | 70.036% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -20.575% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.101% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -265.914% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -30.852% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -141.88% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -12.193% |
| AVAX Technologies, Inc. | 6.69 Million USD | 157.078% |
| Zenith Capital Corp. | -8.94 Million USD | 57.283% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.081% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -21828.403% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -55.587% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -2127.367% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -90.554% |
| Kadimastem Ltd | -3.04 Million USD | -25.652% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -288.205% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -204.152% |
| BioStem Technologies, Inc. | -7.77 Million USD | 50.891% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -2004.938% |
| LadRx Corporation | -3.82 Million USD | 0.091% |
| Cell Source, Inc. | -4.32 Million USD | 11.68% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -456.103% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -456.103% |
| NovAccess Global Inc. | -2.46 Million USD | -54.865% |
| Affymax, Inc. | -15.04 Million USD | 74.61% |
| Itoco Inc. | -919.14 Thousand USD | -315.622% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 9.868% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -241.389% |
| Mobile Lads Corp. | -554.55 Thousand USD | -588.873% |
| CytoDyn Inc. | -18.05 Million USD | 78.845% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -15077.382% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1635.815% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -576.464% |
| SYBLEU INC | -149.18 Thousand USD | -2460.764% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -110.323% |
| International Stem Cell Corporation | -663 Thousand USD | -476.191% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -7157.118% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -18681.45% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 89.466% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -136.103% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -419.158% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -22.795% |
| Neutra Corp. | -229.48 Thousand USD | -1564.654% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 78.219% |
| PureTech Health plc | -146.19 Million USD | 97.387% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 82.225% |
| IXICO plc | -1.43 Million USD | -165.842% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 59.75% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 96.864% |
| CSL Limited | 3.81 Billion USD | 100.1% |
| Cellectis S.A. | -108.85 Million USD | 96.491% |